Current Research into Cures for Type-1 Diabetes

Sometimes clinical trials are terminated while on going.

These researchers are testing Tolimidone (also known as MTX228), which has a long history.

OPT101 is a small peptide (a type of protein) designed to target CD40, which plays a central role in the inflammatory autoimmune response that damages the insulin-producing beta cells in people with T1D.

RD13-02 uses specially engineered immune cells designed to remove certain immune cells believed to drive the autoimmune attack that damages insulin-producing beta cells.

Back in April, I blogged about a Phase-II study called "Anti-Thymocyte Globulin and Verapamil Start A Phase-2 Clinical Trial" (NCT06455319).

A new clinical trial is testing Rezpegaldesleukin, also known as NKTR-358, or REZPEG, as a potential treatment to slow or stop T1D in honeymooners.

Pancreatic islet transplantation is an approach designed to restore the body’s ability to produce insulin by transplanting beta cells (insulin-producing cells) from a donor pancreas.

Researchers at the University of Florida are launching a new Phase 2 clinical trial to evaluate a combination therapy for individuals recently diagnosed with type 1 diabetes.

GentiBio, Inc. is sponsoring a clinical trial known as POLARIS, which aims to evaluate a cell therapy called GNTI-122 in honeymoon adults.

Researchers at the University of Miami are exploring whether a combination of two well-known supplements—omega-3 fatty acids and vitamin D—might help preserve insulin production in people with type 1 diabetes.

An open letter to everyone who cares about research aimed at type 1 diabetes cures.

The treatment being tested is called Brivekimig (previously SAR442970).

A new clinical trial is exploring whether two different immune therapies, used alone or in combination, can delay or prevent the onset of T1D in people who are at high risk, but have not yet been diagnosed with T1D.

The Fecal Autologous Capsule Transplantation for Type 1 Diabetes Mellitus (FACT-T1D) trial is testing a new approach to treating or curing type 1 diabetes.

CNK-UT009, as tested here, is a one-time infusion of living cells designed to modify the immune system’s behavior.

IMMUNOSTEM technology refers to using a virus (specifically a lentivirus) to deliver a new gene into cells, which will then produce a specific protein PD-L1 (Programmed Death-Ligand 1).

Baricitinib works by interfering with signaling pathways inside immune cells, to reduce inflammation and lower the immune system.

This blog posting reports on the results of Avotres recent phase-I clinical trial into AVT001 and the company's future plans for testing.

I have not posted anything in this blog for the last 5 weeks, and I don't expect to for the next few weeks.

This clinical trial tested whether long-term daily treatment with Remygen®, an oral drug developed by Diamyd Medical, could help restore insulin production in adults with longstanding type 1 diabetes (T1D).

I'm going to start using generative AI (what people call "chatbot" technology) to help me create draft blog postings.

This blog post reports on some news that I consider exciting, for at least two different reasons: first because it might be an early milestone on a path that leads to a practical cure of established T1D.

TIX100 is a protein which inhibits the action of TIXNP (thioredoxin-interacting protein).

This is the most fun I have had writing a blog in a long time.

Denosumab is a monoclonal antibody, which is already approved for several bone related diseases and is sold under the names Wyost, Xgeva, Prolia, and Jubbonti.

Last year, at the start of the year, I published a blog of four research projects I was looking forward to updates in the new year.

Normally, sometime in October, I write a summary of all the clinical trials funded by JDRF.

Fenofibrate (also spelled Phenofibrate) is commonly prescribed for high cholesterol and high triglycerides.